News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Ipsen is to buy Merrimack’s pancreatic cancer drug, Onivyde, plus a generic cancer drug, in a deal potentially worth more than $1 billion.
News Shire's Onivyde pancreatic cancer drug approved in EU Shire’s Onivyde has been approved in a group of advanced pancreatic cancer patients in Europe.
News Shire's Onivyde recommended by EU regulators Europe’s top scientific committee has recommended Shire’s Onivyde (irinotecan pegylated liposomal formulation) for advanced pancreatic cancer.
News ASCO: Novartis touts Kisqali adjuvant breast cancer data Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.